MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference

LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the virtual Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 10:30 a.m. ET.

Dr. Forbes will also participate on a panel discussion titled “The Next Big Thing in Vector Gene Therapy—Non-traditional Vectors and Gene Regulation” taking place on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the company presentation will be available on the Investors page of the Company’s website at A replay of the webcast will be available for approximately 30 days following the presentation.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit




Real Chemistry
Ben Rickles
(404) 502-6766


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.